Single Shot Liposomal Bupivicaine in Rotator Cuff Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

October 24, 2018

Primary Completion Date

January 22, 2020

Study Completion Date

January 22, 2020

Conditions
Rotator Cuff TearPain, Postoperative
Interventions
DRUG

liposomal bupivicaine

"The medication administered in the interscalene block is the intervention in this study. There are three different types of interscalene blocks that will be administered in order to compare the independent effectiveness of LB with the effectiveness of LB plus dexamethasone. Study participants will be randomized into one of three groups. The treatment groups are listed below:~Group 1 (Control): 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone Group 2: 15ml 0.5% bupivacaine and 10ml (133mg) of LB (Exparel) and 5.4ml normal saline Group 3: 5ml 0.5% bupivacaine and 10ml LB (Exparel) and 0.4ml (4 mg) dexamethasone and 5ml normal saline"

DRUG

Dexamethasone

steroid that will be used in control as well as in group 3 to see if effect with liposomal bupivicaine is prolonged as has been shown with standard bupivicaine.

Trial Locations (1)

46123

American Health Network, Avon

All Listed Sponsors
lead

Indiana University

OTHER

NCT03822182 - Single Shot Liposomal Bupivicaine in Rotator Cuff Surgery | Biotech Hunter | Biotech Hunter